Table 1.
Characteristics of the patients.
| Characteristics | Lenvatinib plus camrelizumab group (n = 48) | Lenvatinib monotherapy group (n = 44) | P |
|---|---|---|---|
| Age (years) | 53.81 ± 15.75 | 54.86 ± 18.25 | 0.692 |
| Sex, male, n (%) | 43 (89.6) | 40 (90.9) | 0.831 |
| BMI (kg/m2) | 22.33 ± 2.89 | 22.66 ± 3.09 | 0.600 |
| ECOG PS, n (%) | 0.984 | ||
| 0 | 20 (41.7) | 18 (40.9) | |
| 1 | 21 (43.8) | 19 (43.2) | |
| 2 | 7 (14.6) | 7 (15.9) | |
| Platelets (×109/L) | 193.60 ± 86.13 | 187.77 ± 81.80 | 0.740 |
| Total bilirubin (μmol/L) | 18.72 ± 9.21 | 18.91 ± 8.89 | 0.920 |
| Albumin (g/L) | 36.79 ± 6.91 | 37.70 ± 6.45 | 0.504 |
| Child-Pugh score, n (%) | 0.752 | ||
| ≤7 | 41 (85.4) | 40 (90.9) | 0.417 |
| >7 | 7 (14.6) | 4 (9.1) | |
| AFP, n (%) | 0.513 | ||
| ≤200 ng/mL | 24 (50.0) | 25 (56.8) | |
| >200 ng/mL | 24 (50.0) | 19 (43.2) | |
| Maximal diameter of tumor (cm) | 9.95 ± 6.9 | 9.28 ± 4.6 | 0.508 |
| Number of tumors, n (%) | 0.638 | ||
| ≤3 | 9 (18.8) | 10 (22.7) | |
| >3 | 39 (81.2) | 34 (77.3) | |
| BCLC stage, n (%) | 0.639 | ||
| B | 6 (12.5) | 7 (15.9) | |
| C | 42 (87.5) | 37 (84.1) | |
| Vascular cancerous emboli, n (%) | 36 (75) | 34 (77.3) | 0.799 |
| Intrahepatic metastasis, n (%) | 37 (80.4) | 34 (77.3) | 0.713 |
| Distant metastasis, n (%) | 21 (43.8) | 19 (43.2) | 0.956 |
| ALBI, n (%) | 0.707 | ||
| 1 | 16 (33.3) | 17 (38.6) | |
| 2 | 28 (58.3) | 25 (56.8) | |
| 3 | 4 (8.3) | 2 (4.5) | |
| HBV infection, n (%) | 41 (85.4) | 38 (86.4) | 0.896 |
| Received previous treatment for HCC or not | 0.452 | ||
| Yes | 32 (66.7%) | 26 (59.1%) | |
| No | 16 (33.3%) | 18 (40.9%) | |
| Previous treatment(s) for HCC | |||
| Surgery | 11 (22.9%) | 10 (22.7%) | 0.983 |
| Ablation | 10 (20.1%) | 9 (20.5%) | 0.964 |
| TACE or TAE | 14 (29.2%) | 10 (22.7%) | 0.482 |
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ALBI, assessment of the albumin-bilirubin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TAE, transarterial embolization; TACE, transarterial chemoembolization.